Compare FVCB & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FVCB | CGEN |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.0M | 270.4M |
| IPO Year | 2018 | 2001 |
| Metric | FVCB | CGEN |
|---|---|---|
| Price | $16.26 | $2.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $18.00 | $5.00 |
| AVG Volume (30 Days) | 178.5K | ★ 570.9K |
| Earning Date | 04-21-2026 | 05-18-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ 47.56 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,781,000.00 | N/A |
| Revenue This Year | $13.83 | N/A |
| Revenue Next Year | $7.45 | $75.09 |
| P/E Ratio | $45.80 | ★ N/A |
| Revenue Growth | ★ 13.87 | N/A |
| 52 Week Low | $11.13 | $1.30 |
| 52 Week High | $16.35 | $3.24 |
| Indicator | FVCB | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 61.85 | 32.63 |
| Support Level | $15.28 | $1.46 |
| Resistance Level | $16.26 | $2.35 |
| Average True Range (ATR) | 0.32 | 0.17 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 90.87 | 1.59 |
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.